CSIMarket Company Name, Ticker, Competitors, else..
 
Eli Lilly And Company  (LLY)
Other Ticker:  
 
 
Price: $593.7675 $1.91 0.322%
Day's High: $592.04 Week Perf: -1.22 %
Day's Low: $ 587.18 30 Day Perf: 7.19 %
Volume (M): 85 52 Wk High: $ 629.97
Volume (M$): $ 50,081 52 Wk Avg: $446.93
Open: $592.20 52 Wk Low: $302.14



 Market Capitalization (Millions $) 534,272
 Shares Outstanding (Millions) 900
 Employees 35,000
 Revenues (TTM) (Millions $) 32,073
 Net Income (TTM) (Millions $) 4,988
 Cash Flow (TTM) (Millions $) -237
 Capital Exp. (TTM) (Millions $) 2,878

Eli Lilly And Company
We discover, develop, manufacture, and sell products in one significant business segment'pharmaceutical products. Operations of our animal health business segment are not material to our financial statements. We manufacture and distribute our products through owned or leased facilities in the United States, Puerto Rico, and 17 other countries. Our products are sold in approximately 140 countries.


   Company Address: Lilly Corporate Center Indianapolis 46285 IN
   Company Phone Number: 276-2000   Stock Exchange / Ticker: NYSE LLY
   LLY is expected to report next financial results on February 21, 2024. Next quarterly dividend pay out on December 11, 2023.


Customers Net Income grew by LLY's Customers Net Profit Margin grew to

4.14 %
4.02 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        2.06% 
ABT        1.46% 
BMY   -1.22%    
JNJ        1.11% 
MRK        0.06% 
PFE   -0.21%    
• View Complete Report
   



Enveric Biosciences Inc

The company announced operating shortfall in the third quarter of 2023

After the leaders in the Major Pharmaceutical Preparations sector, some overlooked businesses are impending with the respective earnings. ENVB said it has realized operating shortfall of $-3.448395 million, for the third quarter of 2023.

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Announces Revenue of $0.016 Million, Paving the Way for an Investor Opportunity



Cyclacel Pharmaceuticals Inc, a renowned biopharmaceutical company, recently released its financial results for the third quarter of 2023. While the revenue figures may seem low at $0.016 million, it is crucial to understand the context behind this decline. Despite the net deficit of $-5.982 million, larger than the previous year, strategic factors and upcoming events indicate that Cyclacel Pharmaceuticals Inc may present a significant opportunity for investors.
Revenue Insights and Future Expectations
Cyclacel Pharmaceuticals Inc's third-quarter revenue of $0.016 million reflects a temporary setback. However, it is essential to note that pharmaceutical companies often face fluctuations in revenue due to various factors such as drug development timelines, regulatory approvals, and clinical trials. These figures do not accurately reflect the long-term growth potential and overall strength of the company.
Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc Faces Fiscal Disarray as Revenue Plummets

Financial News Report: Arrowhead Pharmaceuticals Inc Announces Q4 2023 Earnings
Arrowhead Pharmaceuticals Inc has reported its financial results for the fourth quarter of 2023 earnings season, revealing a significant increase in its loss per share. The company recorded a loss of $-1.02 per share, compared to $-0.81 per share in the same quarter the previous year, and a growth in loss from $-0.96 per share from the previous quarter.
Additionally, the company's revenue for the quarter declined by -49.02% to $16.10 million, down from $31.58 million in the same quarter a year before. However, sequentially, the revenue grew by 1.719% from $15.83 million.
Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc. Faces Setback with Operating Loss in Q3 2023



Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.
Earth Science Tech Inc

The company released Revenue of $1.92772 million, in the fiscal interval closing September 30 2023



Earth Science Tech Inc, a leading company in the science and wellness industry, has recently released its financial results for the fiscal interval closing September 30, 2023. The results indicate a significant improvement in revenue, earnings, and profit margins. Additionally, the company's stock performance has been impressive, reflecting strong investor confidence. This article will outline the key facts from the financial results and provide an overview of the context surrounding Earth Science Tech Inc's recent achievements.
Financial Results:
1. Revenue: Earth Science Tech Inc achieved revenue of $1.92772 million in the fiscal interval closing September 30, 2023. This represents a substantial increase compared to the same quarter the previous year.





 

Eli Lilly's Segments
 
Neurosciences
 Segment     of total Revenue
Endocrinology
 Segment     of total Revenue
Oncology
 Segment     of total Revenue
Animal health
 Segment     of total Revenue
Cardiovascular
 Segment     of total Revenue
Other pharmaceutical
 Segment     of total Revenue
Zyprexa
 Segment     of total Revenue
Humulin
 Segment     of total Revenue
Humalog
 Segment     of total Revenue
Evista
 Segment     of total Revenue
Cymbalta
 Segment     of total Revenue
Strattera
 Segment     of total Revenue
Alimta
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  • Revenue Outlook
Eli Lilly does not provide revenue guidance.

• Earnings Outlook
Eli Lilly And Company issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
Europe
Other foreign countries




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com